CLINICAL_TRIALS
trial_result
· 2022-08-01
Clinical Trial Update: An Efficacy and Safety Study of Palovarotene for the Treatment of MO [Phase 2]
Summary
A Phase 2 clinical trial evaluating palovarotene for exostoses in multiple hereditary exostosis terminated with posted results in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Clementia Pharmaceuticals Inc. | Conditions: Exostoses, Multiple Hereditary | Phase 2 | Status: TERMINATED | Results posted: 2022-08-01